PMF患者快速进展为骨髓纤维化的ARCH/CHIP相关突变研究
该研究对比了77例经随访骨髓活检证实从0级进展至2/3级纤维化的PMF患者与27例未发生纤维化的prefibrotic PMF患者,中位随访分别为6.2年和7.3年。结果显示,初诊时可检测到的ARCH/CHIP罕见突变(SRSF2、U2AF1、SF3B1、IDH1/2、EZH2)在 later 发生纤维化组占24.7%,而未发生纤维化组未检出(P=0.0028);常见ARCH/CHIP突变(TET2、ASXL1、DNMT3A)与纤维化进展无关。亚组32例的肿瘤突变负荷无显著差异(7.68 vs 6.85 mutations/MB)。结论认为,初诊时即存在的ARCH/CHIP罕见突变是快速纤维化进展(中位2.0年)的独立风险因素。
要点
- 初诊时ARCH/CHIP罕见突变(SRSF2、U2AF1、SF3B1、IDH1/2、EZH2)与PMF快速纤维化进展相关。
- 常见ARCH/CHIP突变(TET2、ASXL1、DNMT3A)与纤维化进展无关。
- PMF初诊时应关注ARCH/CHIP罕见突变以识别快速进展高风险患者。
核心结论
- 初诊时即存在的ARCH/CHIP罕见突变(SRSF2、U2AF1、SF3B1、IDH1/2、EZH2)是PMF快速纤维化进展(中位2.0年)的独立风险因素。
研究设计与样本
- 回顾性比较研究,纳入77例经随访骨髓活检证实从0级进展至2/3级纤维化的PMF患者(中位随访6.2年)与27例未发生纤维化的prefibrotic PMF患者(中位随访7.3年)。
主要发现
- 初诊时可检测到的常见ARCH/CHIP相关突变(TET2、ASXL1、DNMT3A)与纤维化进展无关。
- ARCH/CHIP罕见突变(SRSF2、U2AF1、SF3B1、IDH1/2、EZH2)在 later 发生纤维化组占24.7%,未发生纤维化组未检出(P=0.0028)。
- 亚组32例的肿瘤突变负荷(TMB)无显著差异(7.68 mutations/MB vs. 6.85 mutations/MB)。
临床怎么用
- 对初诊PMF患者可检测ARCH/CHIP罕见突变(SRSF2、U2AF1、SF3B1、IDH1/2、EZH2)以识别快速纤维化进展高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides histopathological findings there are no indicators of increased risk for fibrotic progression in myeloproliferative neoplasms (MPN). Age-related clonal hematopoiesis (ARCH/CHIP) is a frequent finding in the elderly and combinations with MPN driver mutations (JAK2, MPL, and CALR) have been described. To determine the impact of ARCH/CHIP-related mutations for development of fibrosis in primary myelofibrosis (PMF), the mutational status of cases with fibrotic progression from grade 0 to grade 2/3 (n = 77) as evidenced by follow-up bone marrow biopsies (median 6.2 years) was compared with prefibrotic PMF samples without development of fibrosis (n = 27; median follow-up 7.3 years). Frequent ARCH/CHIP-associated mutations (TET2, ASXL1, and DNMT3A) demonstrable at presentation were not connected with fibrotic progression. However, mutations which are rarely found in ARCH/CHIP (SRSF2, U2AF1, SF3B1, IDH1/2, and EZH2) were present in 24.7% of cases with later development of fibrosis and not detectable in cases staying free from fibrosis (P = 0.0028). Determination of the tumor mutational burden (TMB) in a subgroup of cases (n = 32) did not show significant differences (7.68 mutations/MB vs. 6.85 mutations/MB). We conclude that mutations rarely found in ARCH/CHIP provide an independent risk factor for rapid fibrotic progression (median 2.0 years) when manifest already at first presentation.
引用
- Bartels S, Faisal M, Büsche G, et al. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. 2019. PMID: 31776465. doi:10.1038/s41375-019-0668-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。